Partex NV Forges Collaboration with Sanofi in AI-Based Dossier Enrichment for Out-Licensing

Frankfurt, Germany; 14 March 2024 Partex Group, a pioneer in AI-driven drug discovery, today announces a collaboration with global pharmaceutical giant Sanofi, aimed at using Partex’s advanced AI technology to enhance the value of Sanofi’s out-licensing portfolio.

Building upon the success of a pilot project conducted in 2022, this new collaboration centers around the expansion of an innovative approach which leverages Partex’s AI arm, Innoplexus, and its proprietary AI technology to identify new indications within Sanofi’s out-licensing portfolio. Through meticulous indication expansion, prioritization, and lab validation studies, the collaboration endeavours to uncover fresh prospects for Sanofi’s out-licensing portfolio.

As a crucial component of this collaboration, Innoplexus will embark on a journey to scan, analyse, and enrich multiple out-licensing asset candidates, spanning therapeutic areas. The overarching vision is to explore avenues for repurposing or repositioning these assets for out-licensing focusing on patients’ needs.

Dr. Gunjan Bhardwaj, CEO of Partex, expresses enthusiasm about this innovative milestone collaboration, stating, “Our collaboration with Sanofi exemplifies our dedication to driving innovation in drug discovery. By harnessing the power of AI, we aspire to unlock the hidden potential within Sanofi’s out-licensing portfolio and bring hope to patients suffering from unmet medical needs. This collaboration is a testament to our shared commitment to advancing healthcare through cutting-edge technology.”

The collaboration is already in motion, with the selection of the first three assets for AI predictions, set to be completed in 2024.

Featured News

on June 3, 2024

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	The cookies are used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is used to store whether or not a user has consented to the use of cookies. It does not store any personal data.

Latest Posts

What’s New in Ontosight^® Terminal 1.1

3

Partex and Singapore’s Experimental Drug Development Centre collaborate to bring forward an innovative approach for early drug discovery and development

23

Partex Partners with Lupin to Revolutionize Drug Discovery through AI-Driven Asset Search and Evaluation

Partex NV Forges Collaboration with Sanofi in AI-Based Dossier Enrichment for Out-Licensing

Featured News

Partex and Singapore’s Experimental Drug Development Centre collaborate to bring

Partex Partners with Lupin to Revolutionize Drug Discovery through AI-Driven

Partex NV announces collaboration with Althea DRF Lifesciences to provide

Innovative AI technology in oncology: Partex Group presents results from